Home
Resources
Publications
Does Variant Histology Change Management of Non-muscle-invasive Bladder Cancer?

Does Variant Histology Change Management of Non-muscle-invasive Bladder Cancer?

Maximilian Burger, Ashish M Kamat, David McConkey

Eur Urol Oncol. 2019 Aug 6;S2588-9311(19)30093-8.

PMID: 31395481

Abstract:

A 52-yr-old man, 35 pack-year smoker, is diagnosed with two non-muscle-invasive urothelial tumors, pTa and pT1, the former upstaged to pT1 by a reference pathologist. Two possible treatment strategies include intravesical bacillus Calmette-Guérin (BCG) and/or primary or rescue cystectomy. The importance or even accurate existence of "variant histology" is put into perspective, and whether the reference pathologist's diagnosis of a micropapillary variant requires a real change in treatment strategy is considered. PATIENT SUMMARY: The reference urologist diagnosed two small bladder tumors as two different depths of infiltration: one as pTa and the other (slightly more severe) as pT1. Suspecting a variant, the reference urologist referred to a second pathologist, who upstaged the less severe tumor to T1, with both defined as micropapillary cancer. This presentation discusses removal of the bladder versus a trial of treatment with bladder preservation.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP331002701	PT1		331002-70-1	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: